stars 1 stars 2 stars 3

SIMABS NV has developed a unique platform for fast, flexible and cost effective development and manufacturing of monoclonal antibodies. We deliver total solutions for your development and manufacturing by means of a new and unique manufacturing platform based on continuous bioprocessing. This platform allows us to produce several complex antibodies (monoclonal, bispecific, multivalent,…) in a range from milligrams to kilograms for biopharmaceutical companies. This platform will enable personalised medicine to become an affordable reality. We are a one stop shop with a lean and customer oriented project management approach. SIMABS offers additional services like: • Cell line development • USP/DSP development • Analytical and formulation development • Quality Management • Validation • Project Management • Technology Transfer to GMP • Regulatory Affairs • Clinical Research Contact us to learn more about our pharmaceutical contract development and manufacturing capabilities.

simAbs Questions

Bart van Acker is the Founder and Managing Director of simAbs.

17 people are employed at simAbs.

Top simAbs Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users